This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04124406
Recruitment Status : Active, not recruiting
First Posted : October 11, 2019
Last Update Posted : November 1, 2023
Mayo Clinic
Information provided by (Responsible Party):
Exact Sciences Corporation

Brief Summary:
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.

Condition or disease Intervention/treatment
Colon Cancer Device: Cologuard

Detailed Description:
Participates will be consented for prospective follow-up for health outcomes, which will be ascertained through periodic contacts. Participants will complete a baseline health questionnaire survey (T0) and a 1-year follow-up questionnaire survey (T1), allow access to medical records, when available, and allow future contacts for additional surveys.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
Actual Study Start Date : October 18, 2019
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : December 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

Group/Cohort Intervention/treatment
Adults Prescribed Cologuard
Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.
Device: Cologuard
multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test

Primary Outcome Measures :
  1. Enrollment of Subjects [ Time Frame: 3 years ]
    Enrollment of 150,000 subjects

Secondary Outcome Measures :
  1. Diagnostic colonoscopy [ Time Frame: 4.5 years ]
    Proportion having diagnostic colonoscopy within 1 year after positive CG test

  2. CRC Frequency [ Time Frame: 10 years ]
    Frequency of CRC among enrollees

  3. National Rates Comparison [ Time Frame: 10 years ]
    Comparison with national rates (i.e., SEER cancer registry rates) adjusted to reflect a) the age- and sex- distribution of CG users, b) that 25% of colorectal cancers occur in high risk patients, and c) the attrition rate of our longitudinal cohort

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Adults prescribed Cologuard for routine colon cancer screening by their healthcare provider.

Inclusion Criteria:

  • Resident of the United States
  • Age 18 years or older
  • Able to provide informed consent
  • Able to complete surveys in English or Spanish
  • Valid order for Cologuard screening

Exclusion Criteria:

  • N/A

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04124406

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Exact Sciences Corporation
Mayo Clinic
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Exact Sciences Corporation Identifier: NCT04124406    
Other Study ID Numbers: 2019-08
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: November 1, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie the results reported in publications of the study will be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol (including statistical methods), informed consent form, and clinical study report will also be shared. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data will be available from 2 years and ending 4 years after publication.
Access Criteria: Proposals for access to data should be directed to To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/EC approvals or waivers as applicable to conduct research.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases